Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CLRB | PRESS-RELEASE | bullish | 6/10 | Cellectar Biosciences reported positive subgroup data from its Phase 2b CLOVER WaM trial of iopofosine I 131 in Waldenst | Oct 15, 2026 |
| ANL | PRESS-RELEASE | neutral | 4/10 | Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA for cetuximab, t | Oct 15, 2026 |
| AQST | PRESS-RELEASE | bullish | 7/10 | Aquestive Therapeutics announced FDA acceptance of its resubmitted NDA for Anaphylm (dibutepinephrine) sublingual film a | Oct 15, 2026 |
| IMCR | PRESS-RELEASE | neutral | 4/10 | Immunocore dosed the first patient in a Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate for | Oct 15, 2026 |
| ZYME | PRESS-RELEASE | neutral | 1/10 | Zymeworks Inc. announced it will report its Q3 2026 results on November 9, 2026. | Oct 15, 2026 |
| CHRS | PRESS-RELEASE | neutral | 4/10 | Coherus Oncology announced it will release interim clinical data for tagmokitug (anti-CCR8 antibody) combined with torip | Oct 14, 2026 |
| CNTN | PRESS-RELEASE | neutral | 3/10 | Canton Strategic Holdings released its Q3 2026 ecosystem report highlighting governance milestones, six new Super Valida | Oct 14, 2026 |
| RYTM | PRESS-RELEASE | bullish | 6/10 | Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan for acquired hypothalamic ob | Oct 13, 2026 |
| GENB | PRESS-RELEASE | bullish | 6/10 | Generate Biomedicines announced a multi-target collaboration with Zealand Pharma to develop multispecific protein therap | Oct 13, 2026 |
| BMEA | PRESS-RELEASE | neutral | 5/10 | Biomea Fusion announced Phase 1 data for oral GLP-1 RA BMF-650 showing 1.5%-3.2% weight reduction at Day 29 in outpatien | Oct 13, 2026 |
| AGMB | PRESS-RELEASE | bullish | 6/10 | Agomab Therapeutics dosed the first patient in its Phase 2b NOV-ERA trial of ontunisertib for Fibrostenosing Crohn's dis | Oct 13, 2026 |
| TCRT | PRESS-RELEASE | bullish | 8/10 | Alaunos Therapeutics completed the acquisition of Velaris Therapeutics in a reverse merger, concurrently raising $350 mi | Oct 13, 2026 |
| APUS | PRESS-RELEASE | neutral | 3/10 | MindWave Innovations, a subsidiary of APUS, announced that its NILA token will be listed on the Pionex exchange starting | Oct 13, 2026 |
| SABS | PRESS-RELEASE | bullish | 5/10 | SAB Biotherapeutics announced FDA Fast Track designation for its lead candidate SAB-142, a disease-modifying immunothera | Oct 13, 2026 |
| SCNX | PRESS-RELEASE | bearish | 5/10 | Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, a 256% sequential increase from Q2 2026's $344K, dri | Oct 13, 2026 |
| OTLK | PRESS-RELEASE | neutral | 3/10 | Outlook Therapeutics participated in a Virtual Investor segment featuring its new CFO Kevin Lundquist, who discussed the | Oct 6, 2026 |
| GRML | PRESS-RELEASE | neutral | 4/10 | Greenland Mines announced a $20 million share repurchase authorization, following recent capital raises totaling over $5 | Oct 6, 2026 |
| PACB | PRESS-RELEASE | neutral | 4/10 | PacBio announced a collaboration with TychoBio, an AI drug discovery company, to generate full-length RNA data using Pac | Oct 6, 2026 |
| RGEN | PRESS-RELEASE | bullish | 6/10 | Repligen completed its acquisition of BioLife Solutions, paying $11.25 per share in cash plus 0.1442 shares of Repligen | Oct 6, 2026 |
| SXTP | PRESS-RELEASE | neutral | 6/10 | 60 Degrees Pharmaceuticals announced it will conclude enrollment in its Phase 2 severe babesiosis study at 30 patients ( | Oct 6, 2026 |
| GALT | PRESS-RELEASE | bullish | 7/10 | Galectin Therapeutics announced it submitted a registrational Phase 3 protocol for belapectin (MASH cirrhosis/portal hyp | Oct 6, 2026 |
| BBIO | PRESS-RELEASE | bullish | 7/10 | BridgeBio announced FDA acceptance of its NDA for oral infigratinib in achondroplasia with Priority Review and a PDUFA d | Oct 6, 2026 |
| SCYX | PRESS-RELEASE | neutral | 4/10 | SCYNEXIS announced completion of a Phase 1 study for SCY-770, a first-in-class oral direct AMPK activator for ADPKD, sho | Oct 6, 2026 |
| PMN | PRESS-RELEASE | neutral | 3/10 | ProMIS Neurosciences appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Dr. Rubino b | Oct 6, 2026 |
| BHC | PRESS-RELEASE | neutral | 1/10 | Bausch Health Companies Inc. announced it will report its Q3 2026 results on October 28, 2026. | Oct 6, 2026 |
| KMDA | PRESS-RELEASE | bullish | 6/10 | Kamada announced the commercial launch of two new biosimilars in Israel (Ustekinumab-Kamada and Enoxaparin-Kamada), expa | Oct 6, 2026 |
| OKYO | PRESS-RELEASE | bullish | 6/10 | OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NC | Oct 6, 2026 |
| QNTM | PRESS-RELEASE | neutral | 4/10 | Quantum BioPharma announced a Study Start-Up Agreement with Thermo Fisher's PPD clinical research business to initiate i | Oct 6, 2026 |
| SYRE | PRESS-RELEASE | bearish | 6/10 | Spyre Therapeutics priced a $350M underwritten public offering of 4,117,648 shares at $85.00/share, with an underwriter | Oct 5, 2026 |
| VOR | PRESS-RELEASE | neutral | 2/10 | Vor Bio granted stock options and RSUs to 9 newly hired employees as inducement awards under Nasdaq Rule 5635(c)(4). Thi | Oct 5, 2026 |